Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1291583

Next Previous
X
Search
Drug Profile

BI 1291583

Alternative Names: BI-1291583

Latest Information Update: 16 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antibronchitics
  • Mechanism of Action Dipeptidyl peptidase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchiectasis

Most Recent Events

  • 16 Oct 2024 Boehringer Ingelheim plans a phase I trial in healthy volunteers in October 2024 (PO) (NCT06631417) (EudraCT 2023-510260-13-00)
  • 07 Oct 2024 Boehringer Ingelheim completes the phase II Clairafly™ trial for Bronchiectasis (In adults, In the elderly) in the US, Belgium, Italy, The Netherlands, Spain and Germany (PO, Tablet) (NCT05865886) (EudraCT2022-502835-21-00)
  • 30 May 2024 Boehringer Ingelheim completes a phase II trial in Bronchiectasis (In adults, In the elderly) in the US, Australia, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Korea, Latvia, Mexico, Netherland, Poland, Portugal, Spain, Turkey and United Kingdom (NCT05238675)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top